David Ross Smith
Net Worth

Last updated:

What is David Ross Smith net worth?

The estimated net worth of Mr. David Ross Smith is at least $23,983,678 as of 3 Mar 2022. He owns shares worth $4,094,893 as insider, has earned $12,808,785 from insider trading and has received compensation worth at least $7,080,000 in Charles River Laboratories International, Inc..

What is the salary of David Ross Smith?

Mr. David Ross Smith salary is $1,180,000 per year as Corporation Executive Vice President & Chief Financial Officer in Charles River Laboratories International, Inc..

How old is David Ross Smith?

Mr. David Ross Smith is 59 years old, born in 1966.

What stocks does David Ross Smith currently own?

As insider, Mr. David Ross Smith owns shares in one company:

Company Title Shares Price per share Total value
Charles River Laboratories International, Inc. (CRL) Corporation Executive Vice President & Chief Financial Officer 25,819 $158.6 $4,094,893

What does Charles River Laboratories International, Inc. do?

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

David Ross Smith insider trading

Charles River Laboratories International, Inc.

Mr. David Ross Smith has made 19 insider trades between 2019-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 8,656 units of CRL stock on 19 Feb 2021. As of 3 Mar 2022 he still owns at least 25,819 units of CRL stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 3,304 $144.67 $477,990
Sale
Common Stock 3,825 $281.49 $1,076,715
Sale
Common Stock 858 $284.58 $244,170
Option
Common Stock 1,815 $179.66 $326,083
Sale
Common Stock 387 $285.16 $110,357
Option
Common Stock 3,846 $109.34 $420,522
Option
Stock Options (Right to Buy) 3,846 $109.34 $420,522
Option
Stock Options (Right to Buy) 3,304 $144.67 $477,990
Sale
Common Stock 2,606 $282.56 $736,362
Sale
Common Stock 1,289 $283.41 $365,317
Option
Stock Options (Right to Buy) 1,815 $179.66 $326,083
Sale
Common Stock 1,750 $407.15 $712,518
Sale
Common Stock 3,305 $144.67 $478,134
Option
Common Stock 3,305 $144.67 $478,134
Option
Stock Options (Right to Buy) 3,305 $144.67 $478,134
Option
Common Stock 3,845 N/A N/A
Sale
Common Stock 3,845 N/A N/A
Option
Stock Options (Right to Buy) 3,845 N/A N/A
Sale
Common Stock 2,000 $320 $640,000
Sale
Common Stock 4,366 $88.05 $384,426
Option
Common Stock 4,366 $88.05 $384,426
Option
Stock Options (Right to Buy) 4,366 $88.05 $384,426
Sale
Common Stock 8,656 $291.41 $2,522,436
Sale
Common Stock 5,000 $249.86 $1,249,315
Option
Stock Options (Right to Buy) 3,304 $144.67 $477,990
Option
Common Stock 3,304 $144.67 $477,990
Sale
Common Stock 3,304 $216.62 $715,703
Sale
Common Stock 1,884 $150 $282,600
Sale
Common Stock 4,188 $162.37 $680,022
Option
Common Stock 4,188 $73.7 $308,656
Option
Stock Options (Right to Buy) 4,188 $73.7 $308,656
Option
Common Stock 8,211 $98.7 $810,385
Sale
Common Stock 8,211 $167.46 $1,375,039
Option
Stock Options (Right to Buy) 8,211 $98.7 $810,385
Sale
Common Stock 4,500 $170.29 $766,319
Option
Common Stock 1,249 $76.12 $95,074
Sale
Common Stock 1,249 $130.7 $163,241
Option
Stock Options (Right to Buy) 1,249 $76.12 $95,074
Option
Stock Options (Right to Buy) 2,158 $76.67 $165,454
Sale
Common Stock 2,158 $141.85 $306,112
Option
Common Stock 2,158 $76.67 $165,454

Charles River Laboratories International key executives

Charles River Laboratories International, Inc. executives and other stock owners filed with the SEC: